Quest Diagnostics launched an ultrasensitive blood-based MRD test to monitor multiple myeloma treatment, potentially reducing invasive bone marrow aspirations and associated costs.
Longevity News
Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially spar...
Source: FierceBiotech - Medtech • Published: 20 Feb 2026, 11:32
Continue exploring
Related longevity signals
Frontiers - HealthFrom MRI activity to treatment escalation in relapsing multiple sclerosis: what can new T2 lesions tell us?Assessment of new T2 MRI lesions in relapsing multiple sclerosis and their limits for guiding treatment escalation and individual prognosis.Longevity TechnologyClaremedica’s digital test finds 90% of new dementia cases earlyA report on a primary care group’s adoption of a digital cognitive assessment and what readers will learn about its implementation and uptake.PR NewswireAnbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication ExpansionComparative oncology collaboration examining a selective cancer therapy in naturally occurring animal tumors to guide which human indications and combinations to pursue.Nature - BiotechnologyA CRISPR-based ‘dam-break drainage’ sensing architecture for rapid, affordable and ultrasensitive pathogen detectionA chip-based CRISPR-Cas13a fluidic sensor translates target RNA into a visible dam-break drainage signal for rapid, instrument-free detection.